Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after Covid delays

[cafead]

via An AP analysis of Food and Drug Administration data shows that agency staffers have not returned to roughly 2,000 pharmaceutical manufacturing firms to conduct surveillance inspections since before the pandemic, raising the risks of contamination and other issues in drugs used by millions of Americans.

article source